A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021
Tekijät: Kysenius, Kai; Anttalainen, Anna; Toppila, Iiro; Miettinen, Tatu; Lassenius, Mariann; Lievonen, Juha; Partanen, Anu; Silvennoinen, Raija; Putkonen, Mervi
Kustantaja: Springer Nature
Julkaisuvuosi: 2024
Lehti:: Annals of Hematology
Tietokannassa oleva lehden nimi: Annals of hematology
Lehden akronyymi: Ann Hematol
Vuosikerta: 103
Numero: 8
Aloitussivu: 2931
Lopetussivu: 2943
ISSN: 0939-5555
eISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-024-05865-y
Verkko-osoite: https://doi.org/10.1007/s00277-024-05865-y
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/457142155
Lisätietoja: Kysenius, K., Anttalainen, A., Toppila, I. et al. Correction to: Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021. Ann Hematol (2024). https://doi.org/10.1007/s00277-024-05995-3 ; DOI: 10.1007/s00277-024-05995-3
Advances in treatment have improved the survival of multiple myeloma (MM) patients, but the disease remains incurable. Here, in this nationwide retrospective real-world evidence (RWE) study, we report the patient characteristics, incidence, overall survival outcomes, comorbidities, and healthcare resource utilization (HCRU) of all adult MM patients diagnosed between 2000 and 2021 in Finland. A total of 7070 MM patients and their 21,210 age-, sex- and region-matched controls were included in the analysis. The average MM incidence doubled from 4.11 to 8.33 per 100,000 people during the follow-up. The average age-standardized incidence also showed a significant increase over time (2.51 in 2000 to 3.53 in 2021). An increase in incidence was particularly seen in older population, indicative of improved diagnosis praxis. The median overall survival (mOS) of the MM patients and their matched controls was 3.6 and 15.6 years, respectively. The mOS of all MM patients increased significantly from 2.8 years (2000-2004) to 4.4 years (2017-2021) during the follow-up period. Distinctively, in patients who received autologous stem cell transplantation (ASCT), the mOS was 9.2 years, while in patients who did not receive ASCT, the mOS was only 2.7 years. MM patients showed more comorbidities at index and increased HCRU than their matched controls. The longer median survival and decreased risk of death indicate improved treatment outcomes in MM patients in Finland.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
Julkaisussa olevat rahoitustiedot:
This study was funded by Takeda Oy.
